Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.62−0.01 (-0.61%)
Close on Nov 18, 2026Market cap $2.64MP/E –Yield –
Ernexa Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ernexa Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $582.00K, up 755.9% year over year. For fiscal 2024 it was $582.00K, up 755.9% from the year before. Over ten years it grew -31.0% a year on average. The highest annual figure on record is $26.05M in fiscal 2014.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $582.00K | +755.9% |
| FY2023 | Dec 31, 2023 | $68.00K | – |
| FY2022 | Dec 31, 2022 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $5.80M | -70.7% |
| FY2019 | Dec 31, 2019 | $19.81M | -15.1% |
| FY2018 | Dec 31, 2018 | $23.34M | +9.7% |
| FY2017 | Dec 31, 2017 | $21.27M | -4.7% |
| FY2016 | Dec 31, 2016 | $22.31M | -9.0% |
| FY2015 | Dec 31, 2015 | $24.52M | -5.9% |
| FY2014 | Dec 31, 2014 | $26.05M | +9.7% |
| FY2013 | Dec 31, 2013 | $23.75M | -1.3% |
| FY2012 | Dec 31, 2012 | $24.06M | +0.8% |
| FY2011 | Dec 31, 2011 | $23.87M | -5.7% |
| FY2010 | Dec 31, 2010 | $25.31M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $1.00K | -94.1% |
| Q3 FY2024 | Sep 30, 2024 | $487.00K | +854.9% |
| Q2 FY2024 | Jun 30, 2024 | $47.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $47.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $17.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $51.00K | -95.7% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | -100.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.18M | -77.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.48M | -67.8% |
| Q2 FY2020 | Jun 30, 2020 | $754.00K | -85.6% |
| Q1 FY2020 | Mar 31, 2020 | $2.39M | -50.5% |
| Q4 FY2019 | Dec 31, 2019 | $5.17M | -12.7% |
| Q3 FY2019 | Sep 30, 2019 | $4.58M | -23.7% |
| Q2 FY2019 | Jun 30, 2019 | $5.23M | -7.5% |
| Q1 FY2019 | Mar 31, 2019 | $4.83M | -16.1% |
| Q4 FY2018 | Dec 31, 2018 | $5.92M | +11.8% |
| Q3 FY2018 | Sep 30, 2018 | $6.00M | +15.5% |
| Q2 FY2018 | Jun 30, 2018 | $5.65M | +1.8% |
| Q1 FY2018 | Mar 31, 2018 | $5.76M | +10.1% |
| Q4 FY2017 | Dec 31, 2017 | $5.30M | -11.4% |
| Q3 FY2017 | Sep 30, 2017 | $5.20M | -4.5% |
| Q2 FY2017 | Jun 30, 2017 | $5.55M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.23M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.98M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.44M | – |
See a number that looks wrong?